Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: Influence of hepatitis B virus genotype and resistance mutation pattern

Journal of Viral Hepatitis

Volumn 18, Issue 3, 2011, Pages 206-215

  Inoue, J ^a   Ueno, Y ^a   Wakui, Y ^a   Niitsuma, H ^a   Fukushima, K ^a   Yamagiwa, Y ^a   Shiina, M ^a   Kondo, Y ^a   Kakazu, E ^a   Tamai, K ^a   Obara, N ^a   Iwasaki, T ^a   Shimosegawa, T ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic hepatitis B; drug resistance; HBV; rtA200V

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; VIROTHERAPY; VIRUS REPLICATION;

ADENINE; ADOLESCENT; ADULT; AGED; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POINT MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 79851496825     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01301.x     Document Type: Article

References (47)

1. Ganem D, Prince AM,. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129. (Pubitemid 38298992)
2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC,. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 8495-8499. (Pubitemid 21915383)
3. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68. (Pubitemid 28304879)
4. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713. (Pubitemid 26296020)
5. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696. (Pubitemid 36337972)
6. Zoulim F,. Hepatitis B virus resistance to antivirals: clinical implications and management. J Hepatol 2003; 39 (Suppl. 1): S133-S138. (Pubitemid 37222660)
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL,. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717. (Pubitemid 26296021)
8. Delaney IV WE, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841. (Pubitemid 37271680)
9. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-455. (Pubitemid 32167991)
10. Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
11. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297. (Pubitemid 36929407)
12. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089. (Pubitemid 37523785)
13. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-943. (Pubitemid 41627977)
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-2681. (Pubitemid 41007822)
15. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751. (Pubitemid 44958517)
16. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398. (Pubitemid 40770292)
17. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ,. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178. (Pubitemid 351249242)
18. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834.
19. Westland CE, Yang H, Delaney IV WE, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73. (Pubitemid 40188776)
20. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-1209. (Pubitemid 41446860)
21. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507. (Pubitemid 39129351)
22. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M,. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451. (Pubitemid 350047463)
23. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
24. Orito E, Fujiwara K, Tanaka Y, et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006; 35: 127-134.
25. Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006; 78: 1276-1283. (Pubitemid 44387512)
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
27. Takahashi M, Nishizawa T, Gotanda Y, et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol 2004; 11: 392-398. (Pubitemid 38380823)
28. Inoue J, Ueno Y, Nagasaki F, et al. Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis. Virology 2009; 395: 202-209.
29. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911. (Pubitemid 46355274)
30. Melegari M, Scaglioni PP, Wands JR,. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633. (Pubitemid 28081083)
31. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101. (Pubitemid 38040727)
32. Gaia S, Barbon V, Smedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008; 48: 540-547.
33. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290. (Pubitemid 43069209)
34. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ,. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313. (Pubitemid 46374587)
35. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-931.
36. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15: 392-398. (Pubitemid 351473632)
37. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: 891-898. (Pubitemid 46525336)
38. Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39: 42-50. (Pubitemid 38461465)
39. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F,. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-1261. (Pubitemid 44515103)
40. Shaw T, Bartholomeusz A, Locarnini S,. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44: 593-606. (Pubitemid 43227885)
41. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
42. Santantonio T, Fasano M, Durantel S, et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther 2009; 14: 557-565.
43. Qi X, Xiong S, Yang H, Miller M, Delaney WE,. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362. (Pubitemid 46787980)
44. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS,. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-398.
45. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325. (Pubitemid 44214870)
46. Choe WH, Kwon SY, Kim BK, et al., Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28: 814-820. (Pubitemid 351818643)
47. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)